A 83-01

Biological Activity

A-83-01, an inhibitor of TGF-β type I receptor, increased the expression of Myf5 and MyoD, and enhanced myotube formation.The targeting efficacy of single intravenous injections of F-SL combined with A-83-01 was evaluated by measurement of the biodistribution and the antitumor effect in mice bearing murine lung carcinoma M109. A-83-01 temporarily changed the tumor vasculature around 3 h post injection. A-83-01 induced 1.7-fold higher compound accumulation of F-SL in the tumor than liposome alone at 24 h post injection.

*The compound is unstable in solutions, freshly prepared is recommended

Product Citations

• 

  Chemical Engineering Journal. 2025 Apr 24.

  Intracellular and extracellular stiffness regulation in osteosarcoma: Overcoming mechano-immune checkpoints to enhance anti-osteosarcoma immunity
  A 83-01 purchased from AbMole

• 

  Patent. CN119639678A 2025 Mar 18.

  Patent. CN119639678A
  A 83-01 purchased from AbMole

• 

  Cancer Cell. 2024 Apr 8;42(4):535-551.e8.

  Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer
  A 83-01 purchased from AbMole

• 

  Cancer Lett. 2024 Oct 02;605:217284.

  Exploring epigenetic dynamics unveils a super-enhancer-mediated NDRG1-β-catenin axis in modulating gemcitabine resistance in pancreatic cancer
  A 83-01 purchased from AbMole

• 

  Cell Death Dis. 2024 Oct 15;15(10):749.

  USP7 depletion potentiates HIF2α degradation and inhibits clear cell renal cell carcinoma progression
  A 83-01 purchased from AbMole

• 

  Biochim Biophys Acta Gen Subj. 2024 Jan;1868(4):130566.

  Gastric cancer patient-derived organoids model for the therapeutic drug screening
  A 83-01 purchased from AbMole

• 

  Bio Protoc. 2024 Dec 05;14(23):e5129.

  Culture and Characterization of Differentiated Airway Organoids from Fetal Mouse Lung Proximal Progenitors
  A 83-01 purchased from AbMole

• 

  Adv Sci (Weinh). 2023 Jul 23;e2302640.

  Micro-Engineered Organoid-on-a-Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients
  A 83-01 purchased from AbMole

• 

  Patent. CN117074141A 2023 Nov 17.

  Patent. CN117074141A
  A 83-01 purchased from AbMole

• 

  Patent. CN116987669A 2023 Nov 03.

  Patent. CN116987669A
  A 83-01 purchased from AbMole

• 

  Patent. CN114606192A 2023-08-08.

  Patent. CN114606192A
  A 83-01 purchased from AbMole

• 

  Cell Death Dis. 2022 Apr 5;13(4):303.

  KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colorectal cancer organoids by restoring apoptotic response
  A 83-01 purchased from AbMole

• 

  Nat Biomed Eng. 2020 Sep;4(9):863-874.

  High-throughput automated organoid culture via stem-cell aggregation in microcavity arrays
  A 83-01 purchased from AbMole

Customer Product Validations & Biological Datas

	Source	Breast Cancer Res Treat (2017). Figure 6. A 83-01
	Method	MTT assay
	Cell Lines	SKBR3 cells
	Concentrations	1 μM
	Incubation Time	16 h
	Results	As shown in Fig. 6c that A83-01 alone reduced approximately 17% cell migration of JIMT1 and trastuzumab alone inhibited 20% cell migration, while in combination of A83-01 and trastuzumab synergistically inhibited JIMT1 cell migration up to 90%.

Protocol (for reference only)

Cell Experiment
Cell lines
Preparation method
Concentrations
Incubation time

Animal Experiment
Animal models
Formulation
Dosages
Administration

Chemical Information

Molecular Weight	421.52
Formula	C25H19N5S
CAS Number	909910-43-6
Solubility (25°C)	DMSO 24 mg/mL
Storage	-20°C, protect from light, dry, sealed

References

[1] Furutani Y,et.al. J Cell Biochem. Role of endogenous TGF-β family in myogenic differentiation of C2C12 cells.

[2] Taniguchi Y,et.al. Cancer Sci. Enhanced antitumor efficacy of folate-linked liposomal doxorubicin with TGF-β type I receptor inhibitor.

[3] Masayoshi Tojo, et al. Cancer Sci. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta